Takeda initiates development of a plasma-derived therapy for COVID-19 EP News Bureau Mar 4, 2020 Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) being developed to treat infected, high-risk individuals with COVID-19
